By Paul Honda
paul@hondareport.om
Wednesday, Apr. 18, 2007

For those of you who tune in to Mad Money each day at noon on CNBC, you probably remember Jim Cramer touting Yahoo over and over a month or two ago. He was absolutely convinced that Yahoo's stock was on its way back, that its new Panama would prove to be a revenue monster.

Well, he just hit the air with a total undressing of Yahoo's CEO, Terry Simel. "He is the example of someone who overpromises and underdelivers," Cramer said.

I find Cramer usually entertaining and sometimes educational. In this case, though, It was Cramer who overpromised and underdelivered. He was banging the table for Yahoo. Now that Yahoo came up short ... what? YHOO is down 12 percent to 28.31.

I think he's wrong, wrong, wrong about Dendreon, which is on the verge of getting approval from the Food and Drug Administration on or before May 15. (More recently, I'm long on DNDN with my few, paltry deniros because the numbers, if you do your homework, just do not lie.)

In late March, Cramer panned DNDN the day before it soared from 5 to 15, urging shareholders to "Sell! Sell! Sell!" The ones who sold on his word could have missed out. Fortunately, the stock was halted the next morning and didn't return to market until two days later. It has since run up to 25 and slid to 15 before closing at 16.02 today.

Oh well. It's just TV. And as for Dendreon? One of the best analyses of the company and stock came from an online scholar of the company, Wall Diver, on SeekingAlpha, a biotech site. His rebuttal, a collection of information and hard facts, to a weak analysis by an anti-immunotherapy member of the FDA panel is astounding. You may not feel compelled to investigate more about Dendreon's new vaccine for prostate cancer victims, or maybe you will.

Previous Article: Mid-week review
Next Article: Classic Pitchers' Duel

Comments

Post A Comment